An Open-label Study of SG1827 in Subjects With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2025-03-28
Target enrollment:
Participant gender:
Summary
This is a Phase I, open-label, dose escalation and dose expansion study to Evaluate the
Safety, Tolerability and Preliminary Efficacy of SG1827 in subjects with Advanced Solid
Tumors, refractory or resistant to standard therapy, or without available standard or
curative therapy.